http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송만기 한국공업화학회 2020 한국공업화학회 연구논문 초록집 Vol.2020 No.-
코로나19에 대한 백신 개발은 역사상 전례 없는 빠른 속도와 가능한 모든 수단과 방법을 동원하여 현재 전세계적으로 수백개의 백신 개발이 진행중이다. 전통적인 백신 개발 방식인 사백신, 재조합 단백질 백신 외에도 상용화가 거의 된 적이 없는 mRNA, DNA, 재조합 바이러스를 이용한 백신 개발이 신속한 개발 전략으로 활용되고 있다. 팬데믹으로의 급속한 진행과 다수의 사망자 발생 등 심각한 상황이 지속되어 통상 10년이 소요되던 백신 개발이 불과 1년만에 임상 3상 완료를 목전에 두고 있다. 백신을 통한 집단면역형성이 코로나19에 대한 방어에 가장 중요한 수단으로서 신속한 개발이 필요한 상황이지만 빠른 개발에 따른 효능 및 안전성이 충분히 검증되지 않을 수 있는 우려가 있어 이러한 문제를 해결하기 위한 전략이 필요한 상황이다.
송만기(Man Ki Song),이안휘(Ann Hwee Lee),김영호(Young Ho Kim),이정준(Jung Joon Lee),성영철(Young Chul Sung) 한국응용약물학회 1995 Biomolecules & Therapeutics(구 응용약물학회지) Vol.3 No.2
Natural products, total number of 175, were screened to test fox their effect on the replication of human immunodeficiency virus type 1 (HIV-1). Five of them, such as Eriobotrya japonica, Eugenic caryophyllata, Cuscuta chinensis, Glycyrrhiza uralensis, and Coptis chinensis were shown to be effective in inhibiting the replication of HIV-1 in tissue culture and their selectivity indexes were 42, 40, 14, 18 and 65, respectively. To further fractionate Coptis chinensis, which is shown to be highest anti-HIV-1 activity, methanol extracts of Coptis chinensis were fractionated into methylene chloride at pH3, pH10 and water residue. The selectivity indexes of CH₂Cl₂(pH 3), CH₂Cl₂(pH 10) and water residue were 50, 22 and 98 respectively. Our results show that the water residue of Coptis chinensis was the most effective for anti-HIV-1 activity.
김영호,이성우,김항섭,이승호,송만기,성영철,이정준 영남대학교 약품개발연구소 1996 영남대학교 약품개발연구소 연구업적집 Vol.6 No.-
Thirty ellagitannins originated from some Euphorbiaceous plants were tested for the inhibitory activities against AMV reverse transcriptase and replication of HIV-1 using syncytia forming as say. Most of ellagitannins showed strong inhibitory activities against AMV reverse transcriptase. Some ellagitannins including geraniin, mallotusinin, elaeocarpusin, euphorscopin and jolkianin, showed significant inhibitory activities of syncytia formation of supT1 cell line.
이창근,양세환,박수형,송만기,최소영,성영철 대한면역학회 2005 Immune Network Vol.5 No.1
Background: Chronic infection with hepatitis B virus (HBV) affects about 350 million people worldwide, which have a high risk of development of cirrhosis and hepatocellular carcinoma. Treatment of chronic HBV infection relies on IFN-α or lamivudine. However, interferon-α is effective in only about 30% of patients. Also, the occurrence of escape mutations limits the usage of lamivudine. Therefore, the development and evaluation of new compounds or approaches are urgent. Methods: We comparatively evaluated DNA and adenoviral vaccines expressing HBV antigens, either alone or in combined regimens, for their ability to elicit Th1-type immune responses in Balb/c mice which are believed to be suited to resolve HBV infection. The vaccines were tested with or without a genetically engineered IL-12 (mIL-12 N220L) which was shown to enhance sustained Th1-type immune responses in HCV E2 DNA vaccine. Results: Considering the Th1-type cytokine secretion and the IgG2a titers, the strongest Th1-type immune response was elicited by the DNA prime-adenovirus boost regimen in the presence of mIL-12 N220L. In addition, the codelivery of mIL-12 N220L modulated differentially the immune responses by different vaccination regimens. Conclusion: Our results suggest that the DNA prime-adenovirus boost regimen in the presence of mIL-12 N220L may be the best candidate for HBV vaccine therapy of the regimens tested in this study and will be worthwhile being evaluated in chronic HBV patients.
김주영,Youngjoo Choi,Huan H. Nguyen,송만기,Jun Chang 대한면역학회 2013 Immune Network Vol.13 No.6
Influenza virus is one of the major sources of respiratory tract infection. Due to antigenic drift in surface glycoproteins the virus causes annual epidemics with severe morbidity and mortality. Although hemagglutinin (HA) is one of the highly variable surface glycoproteins of the influenza virus, it remains the most attractive target for vaccine development against seasonal influenza infection because antibodies generated against HA provide virus neutralization and subsequent protection against the virus infection. Combination of recombinant adenovirus (rAd) vector-based vaccine and mucosal administration is a promising regimen for safe and effective vaccination against influenza. In this study, we constructed rAd encoding the globular head region of HA from A/Puerto Rico/8/34 virus as vaccine candidate. The rAd vaccine was engineered to express high level of the protein in secreted form. Intranasal or sublingual immunization of mice with the rAd-based vaccine candidates induced significant levels of sustained HA-specific mucosal IgA and IgG. When challenged with lethal dose of homologous virus, the vaccinated mice were completely protected from the infection. The results demonstrate that intranasal or sublingual vaccination with HA-encoding rAd elicits protective immunity against infection with homologous influenza virus. This finding underlines the potential of our recombinant adenovirusbased influenza vaccine candidate for both efficacy and rapid production.
Sublingual Delivery of Vaccines for the Induction of Mucosal Immunity
Byoung-Shik Shim,Youngjoo Choi,In Su Cheon,송만기 대한면역학회 2013 Immune Network Vol.13 No.3
The mucosal surfaces are constantly exposed to incoming pathogens which can cause infections that result in severe morbidity and/or mortality. Studies have reported that mucosal immunity is important for providing protection against these pathogens and that mucosal vaccination is effective in preventing local infections. For many years, the sublingual mucosa has been targeted to deliver immunotherapy to treat allergic hypersensitivities. However, the potential of vaccine delivery via sublingual mucosal has received little attention until recently. Recent studies exploring such potential have documented the safety and effectiveness of sublingual immunization, demonstrating the ability of sublingual immunization to induce both systemic and mucosal immune responses against a variety of antigens, including soluble proteins, inter particulate antigens, and live-attenuated viruses. This review will summarize the recent findings that address the promising potential of sublingual immunization in proving protection against various mucosal pathogens.